The subjects received 40 IU of intranasal human insulin, Novolin R (Novo Nordisk, Denmark) once daily for four weeks before the breakfast with help of a device Via Nase (Kurve technologies Seattle, WA). The administered dose of insulin via intranasal route was fund to be safe with no ...
The more recent faster-acting mealtime insulins, namely faster aspart (NovoNordisk), ultra-rapid lispro (Eli Lilly), and Biochaperone lispro (Adocia), benefit from added excipients that increase subcutaneous blood flow and/or vascular permeability to speed up absorption and by the inclusion of the...
Verfahren zum Herstellung von Insulin-Vorläufern und Verfahren zur Herstellung von Humaninsulindoi:EP0195691 A1Novel human insulin precursors of the formula B-X-Y-A, wherein X and Y are each lysine or arginine, are prepared by culturing a yeast host transformed with a replicable expression ...
Mutations which may be dominantly or recessively inherited from either parent or occur as a de novo mutation in a single gene affect the functioning of the insulin-producing pancreatic β-cells and precipitate a rare form of diabetes termed as monogenic. The worldwide prevalence of the monogenic ...
“Novo Nordisk” Actrapid HM (Austria); Insulin “Novo Nordisk” Velosulin HM (Austria); Insulin Velosulin HM (Israel); Insuman (Brazil, Chile); Insuman Basal (France, Germany); Insuman Infusat (Germany); Insuman Rapid (France, Germany); Novolin R (China, Ecuador, Korea, Mexico, ...
R.N. reports receiving grants from Helmsley Charitable Trust, Dexcom and Insulet, personal fees and others from DreaMed Diabetes Ltd, personal fees from Novo Nordisk and Eli Lilly and grants from Medtronic. In addition, R.N. owns DreaMed Diabetes Ltd stock and has a patent licensed by DreaMed...
The hyperinsulinaemic−euglycaemic clamp was performed after overnight fasting with an insulin infusion rate of 40 mU m–2 min–1 using human insulin (Actrapid, NovoNordisk, Bagsvaerd, Denmark). Infusion of glucose 200 mg/ml was continually adjusted to maintain euglycaemia at 5.0 mmol/l...
The present invention provides pharmaceutical compositions comprising insulin and novel ligands for the His <B10> Zn<2+> sites of the R-state insulin hexamer. The resulting preparations have improved
Gram, Dorte Xenia (Kobenhavn, DK) Application Number: 12/673337 Publication Date: 04/28/2011 Filing Date: 08/15/2008 Export Citation: Click for automatic bibliography generation Assignee: Novo Nordisk A/S (Bagsvaerd, DK) Primary Class: ...
The US Food and Drug Administration's (FDA) advisory committees recommended the approval of two drug combinations of basal insulin with a glucagon-like peptide-1 (GLP-1) receptor agonist for treating adults with type 2 diabetes: one from Bagsvaerd, Denmark–based Novo Nordisk and another from...